India, Nov. 18 -- Actuate Therapeutics, Inc. (ACTU) presented new preclinical data showing that daily oral dosing of its investigational cancer drug elraglusib achieved up to 77% tumor growth inhibition in an aggressive melanoma model. The findings were presented at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026).

Preclinical Results In Melanoma:

In a study involving mice with B16F10 melanoma tumors, once-daily oral elraglusib achieved 50% tumor growth inhibition, while twice-daily dosing achieved 77%. Both dosing schedules significantly reduced tumor weight compared with the control group.

Higher drug exposure was associated with greater antitumor activity, supporting further evaluation of daily...